Romosozumab versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta‐analysis through a Grade Analysis of Evidence

Citations Over TimeTop 12% of 2021 papers

Abstract

Based on the available studies, our current results demonstrate that romosozumab was better than teriparatide both in terms of efficacy and side effects.

Related Papers

• → Osteoporosis in Older Adults(2020)577 cited
• → Teriparatide(2008)122 cited
• → Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment(2008)24 cited
• → Spotlight on Teriparatide in Osteoporosis†(2009)6 cited
• → Pharmacotherapeutic approaches in osteoporosis(2023)